MAPT and frontotemporal dementia: Alternatively, the use of CSF- and blood-based protein biomarkers holds great promise for AD [19, 20, 105] and FTD [21, 106], although in the case of FTD, we still cannot discriminate between underlying FTLD-tau and -TDP pathology.